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Management of advanced ovarian cancer consists of radical surgery
and systemic chemotherapy. Despite a good initial response to chemo-
therapy, most women relapse and eventually develop treatment resis-
tance. As such there is a need for novel therapeutic agents, and one
promising approach is to target tumor angiogenesis. Nintedanib (BIBF
1120) is an orally administered potent blocker of the receptors of vascu-
lar endothelial growth factor (VEGFR-1–3), platelet-derived growth
factor (PDGFR-α/β) and ﬁbroblast growth factor (FGFR-1–3). It has re-
cently been shown to have activity as maintenance treatment for re-
lapsed ovarian cancer in a randomized phase II trial (Ledermann et al.,
2011). In this article, we present one of the patients in the trial, with a
germline BRCA1mutationwho appeared to have experienced therapeu-
tic beneﬁt to nintedanib for an exceptionally prolonged time.⁎ Corresponding author. Fax: +44 1223 217094.
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A 38-year-old BRCA1-positive lady presented in January 2006 at
30 weeks pregnancy with breathlessness and abdominal swelling. In-
vestigations revealed a large pleural effusion, ascites and widespread
peritoneal disease and omental cake. Ascitic ﬂuid was found to contain
malignant serous papillary cells that stained positive for cytokeratin 7
and CA-125, but negative for cytokeratin 20 and calretinin. Her serum
CA-125 was more than 12,000 U/ml.
She was given two cycles of carboplatin, after which she gave birth
to a healthy baby by spontaneous vaginal delivery in March 2006.
Two weeks later she restarted chemotherapy with two cycles of
carboplatin and paclitaxel and her CA-125 came down to 264 U/ml. Op-
timal debulking surgery was performed in May 2006 and this was
followed by four more cycles of carboplatin and paclitaxel, which she
completed in July 2006. Her CA-125 was within the normal range and
contrast-enhanced computed tomography (CT) showed no evidence
of residual disease. In January 2007, after a 5-month treatment-free in-
terval her CA-125 increased to 100 U/ml and a CT scan showed a 2 cm
node in the common iliac chain (Fig. 1A). Based on these ﬁndings, she
was given second-line chemotherapy with ﬁve cycles of epirubicin, cis-
platin and capecitabine. She completed her treatment in June 2007, by
then her CA-125 had normalized and she had a radiological complete
response (CR). In the same month she was entered into the phase II
trial comparing post-chemotherapy maintenance nintedanib (starting
at 250 mg twice daily) with placebo. Upon unblinding of the trial for
analysis of primary endpoint (progression-free survival — PFS) at
9 months, it turned out she was receiving the active drug. Since there
was amaintained clinical beneﬁt, treatmentwith nintedanibwas contin-
ued. She tolerated the treatment well, with only grade 1 toxicities of fa-
tigue, anorexia, nausea and diarrhea. A dose reduction of nintedanib to
200 mg was required in April 2008, and again in May 2009 to 150 mg
due to fatigue and diarrhea. Her Eastern Cooperative Oncology Group
performance status was zero throughout the treatment and she was
able to remain in fulltime employment.
In June 2008 her CA-125 went up from 10 to 24 U/ml and a CT
scan showed enlarged lymph nodes immediately beneath the aortic
bifurcation and in the right common iliac chain, suggesting disease
recurrence (Fig. 1B and C). She continued with nintedanib as the
trial continuation protocol explicitly allowed for the option to remain
Fig 1. (A) Axial contrast-enhanced CT image demonstrating an enlarged lymph node in
the common iliac chain, immediately beneath the conﬂuence of the common iliac
veins, 5 months after ﬁrst-line chemotherapy. (B) Enlarged lymph nodes immediately
beneath the aortic bifurcation and (C) in the right common iliac chain, 1 year after
second-line chemotherapy and starting nintedanib.
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was maintained.
Her disease remained stable for another 30 months. A CT scan
in December 2010 showed a slightly more pronounced enlarge-
ment of the previously identiﬁed lymph nodes (CA-125 was
28 U/ml). 18F-ﬂuorodeoxyglucose (FDG)-positron emission tomog-
raphy (PET) in February 2011 showed 18FDG uptake in the sub-aortic
region and the right common iliac area (Fig. 2). Again, nintedanib was
continued in view of the perceived slow tumor growth, not warranting
an immediate change of therapy. A repeat FDG-PET in November 2011
showed that uptake was still restricted to these lymph nodes, although
these had increased in size (CA-125was 51 U/ml). Given the long inter-
val from relapse and the continued absence of disseminated disease
elsewhere, a decision was made to resect the involved lymph nodes.
After pausing nintedanib for 5 weeks, a laparotomy was performed in
January 2012. Six lymph nodes were removed, four showing mainly
ﬁbrous tissue with interspersed malignant cells (Fig. 3), and the
remaining two were tumor-free.
At the time of surgery she had been on nintedanib for nearly
4.5 years. After surgery had restored the CR status of the patient,oral nintedanib was restarted 4 weeks later, and to date still
continues.
Discussion
Angiogenesis has a major role in ovarian cancer progression. When
tumors outgrow their blood supply, hypoxia causes the stabilization of
hypoxia-inducible factor (HIF)-1α, resulting in the upregulation of
pro-angiogenic factors, particularly VEGF. A number of anti-angiogenic
agents have been tested in phase II trials and have shown single-agent
activity in relapsed ovarian cancer, including the oral multikinase inhib-
itors cediranib and pazopanib (Tagawa et al., 2012). A recent phase II trial
of nintedanib for patients who had just completed chemotherapy for re-
lapsed ovarian cancer has shown a promising impact on PFS at 36 weeks
compared to placebo (Ledermann et al., 2011). This drug was well toler-
ated with no signiﬁcant toxicities except for higher rate of abnormal
liver function tests. Nintedanib is currently being evaluated in a ﬁrst-
line phase III AGO-OVAR 12/LUME-OVAR 1 trial in combination with
carboplatin and paclitaxel and for up to 2 years maintenance therapy.
In the GOG-0218 and ICON7 trials (Burger et al., 2011; Perren et al.,
2011), the addition of bevacizumab (a humanizedmonoclonal antibody
against VEGF) to carboplatin and paclitaxel as the ﬁrst-line treatment
after debulking surgery considerably improved PFS, particularly for
patients at high risk of progression (Perren et al., 2011). Furthermore,
the OCEANS phase III trial showed that the addition of maintenance
bevacizumab to gemcitabine and carboplatin in the second-line setting
for platinum-sensitive disease resulted in signiﬁcant improvement
in PFS (Aghajanian et al., 2012). More recently, the AURELIA trial
also reported improvement in PFS with the addition of bevacizumab
to chemotherapy in platinum-resistant recurrent ovarian cancer
(Pujade-Lauraine et al., 2012). In this case report, the patient re-
lapsed within 6 months after ﬁrst-line therapy, and after achieving
CR to second-line chemotherapy, the interval to reappearance of dis-
ease under long-term anti-angiogenic monotherapy was much
prolonged, suggesting a tumor-suppressive effect of nintedanib in
the absence of visible disease. The cytostatic rather than tumoricidal
nature of anti-angiogenic agents means that long-termmaintenance
therapy is likely to be needed, and an orally-administered drug such
as nintedanib would be preferable provided its efﬁcacy is conﬁrmed
in larger studies.
Anti-tumor therapies are usually discontinued at signs of progres-
sion, but it has been suggested that continuation of anti-angiogenic
agents may still afford clinical beneﬁt even in the presence of pro-
gressive disease. The concept of continuation of anti-angiogenic treat-
ment through progression has been further corroborated by data from
colorectal cancer patients, and is currently being tested in phase III stud-
ies such as the TML trial. In this case report, nintedanib was maintained
despite the reappearance of visible disease, due to a perception of con-
tinued clinical beneﬁt. Tumor growth and the rise in CA125 were slow
in the presence of this drug. The multimodal approach, to also perform
surgical removal of slow-growing disease while anti-angiogenic thera-
py is continued thereafter, has been able to restore her CR status.
Could the perceived clinical beneﬁt of this patient be related to
nintedanib in addition to her BRCA1 mutation? BRCA1/2 mutations in
ovarian cancer patients are associated with better prognosis. This could
be related to the perturbed DNA repair mechanisms in BRCA-deﬁcient
cancer cells,making themmore sensitive toDNA targeting agents and ra-
diotherapy. The relationship between BRCA mutation and angiogenesis
has been explored by Kawai et al. (2002),who demonstrated thatmutat-
ed BRCA1 protein in breast cancer cells was unable to suppress VEGF ex-
pression and secretion as a result of failure of BRCA1 to interact with
estrogen receptor α. Depletion of BRCA1 in breast cancer cells
in vivo could lead to higher levels of VEGF, enhanced vascularization
and reduced cell death (Navaraj et al., 2009). This suggests that anti-
angiogenic strategy may be particularly effective in treating BRCA1-
deﬁcient tumors. Other studies, however, have shown that BRCA1
Fig. 2. Coronal 18FDG-PET and fused 18FDG-PET-CT images demonstrating avid 18FDG uptake in lymph nodes in the sub-aortic region and the right common iliac area.
Fig. 3.Microscopic images of dissected lymph nodes 4.5 years after starting nintedanib
(×200 magniﬁcation). (A) Most of the lymph nodes showedmainly ﬁbrous tissue (top)
with interspersed malignant cells (bottom). (B) Normal lymphoid cells (center) were
interrupted by high grade serous carcinoma (upper left and lower right) with a classi-
cal psammoma body (arrow).
9H.H. Wong et al. / Gynecologic Oncology Reports 3 (2013) 7–10mutation is correlatedwith reducedVEGF levels in breast cancer patients
(Tarnowski et al., 2004), via the regulation of HIF-1α stability by BRCA1
(Kang et al., 2006). Given these conﬂicting ﬁndings, the relationship be-
tween BRCA mutation and angiogenesis in ovarian cancer is worth ex-
ploring in order to optimize future targeted therapies in this group of
patients.Conclusion
Our patient demonstrated a protracted course of disease stabiliza-
tion whilst on nintedanib following early relapse after platinum-
based chemotherapy. The disease was contained within the involved
lymph nodes that had associated ﬁbrosis, for 4.5 years from starting
single-agent maintenance treatment within the phase II trial. This pa-
tient is currently free of disease following surgical resection of residual
disease 6 years from diagnosis. A number of trials have demonstrated
the effectiveness of anti-angiogenic agents in the treatment of relapsed
ovarian cancer. Continuous maintenance treatment with these drugs,
even through disease progression, may have an important role in dis-
ease control. The relationship between angiogenesis and BRCAmutation
is unknown at present and is also worth exploring.Consent
Written informed consent was obtained from the patient for pub-
lication of this case report and any accompanying images. A copy of
the written consent is available for review by the Editor-in-Chief of
this journal on request.Conﬂict of interest statement
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